Please use this identifier to cite or link to this item:
|Title:||Efficacy of vemurafenib in hairy-cell leukemia|
Dyer, Martin J. S.
|Publisher:||Massachusetts Medical Society|
|Citation:||New England Journal of Medicine, 2014, 370 (3), pp. 286-288|
|Abstract:||The BR A F V600E mutation is present in nearly all cases of hairy-cell leukemia. 1 This finding has led to the introduction of BRAF inhibitors for the treatment of chemotherapy-re - sistant hairy-cell leukemia, and patients have had a good response to the oral inhibitor vemu - rafenib. 2-4 Constitutive phosphorylation of both extracellular signal-regulated kinase (ERK) and mitogen-activated protein–ERK kinase (MEK) has been considered to be a direct consequence of BRAF activation, with BRAF inhibition result - ing in cell death through suppression of this pathway in hairy-cell leukemia. However, data to support this theory are limited, since most pa - tients present with pancytopenia. [Opening paragraph]|
|Rights:||Copyright © 2014, Massachusetts Medical Society. Deposited with reference to the publisher’s archiving policy available on the SHERPA/RoMEO website.|
|Appears in Collections:||Published Articles, Dept. of Biochemistry|
Files in This Item:
|nejmc1310849.pdf||Published (publisher PDF)||502.98 kB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.